151 related articles for article (PubMed ID: 18070193)
1. Systemic therapy for metastatic urothelial carcinoma.
Lin CC; Hsu CH; Pu YS; Vogelzang NJ
BJU Int; 2008 Apr; 101(7):795-803. PubMed ID: 18070193
[No Abstract] [Full Text] [Related]
2. Suggestions for regulatory agency approval of second-line systemic therapy for metastatic transitional cell carcinoma.
Sonpavde G; Rosenberg JE; Hahn NM; Galsky MD; Bangs R; Sternberg CN; Vogelzang NJ
J Clin Oncol; 2010 May; 28(13):e205-7; author reply e208. PubMed ID: 20159797
[No Abstract] [Full Text] [Related]
3. Predictive factors for response and prognostic factors for long-term survival in consecutive, single institution patients with locally advanced and/or metastatic transitional cell carcinoma following cisplatin-based chemotherapy.
Jessen C; Agerbaek M; Von Der Maase H
Acta Oncol; 2009; 48(3):411-7. PubMed ID: 18798018
[TBL] [Abstract][Full Text] [Related]
4. Phase III trials in oncology: setting standards of care?
Seeber S; Braun AH
Nat Clin Pract Oncol; 2005 Sep; 2(9):426-7. PubMed ID: 16264993
[No Abstract] [Full Text] [Related]
5. The evolving role of chemotherapy in advanced urothelial cancer.
Calabrò F; Sternberg CN
Curr Opin Support Palliat Care; 2007 Oct; 1(3):180-6. PubMed ID: 18685360
[TBL] [Abstract][Full Text] [Related]
6. Posttreatment prognostic nomogram for patients with metastatic urothelial cancer completing first-line cisplatin-based chemotherapy.
Galsky MD; Moshier E; Krege S; Lin CC; Hahn N; Ecke T; Sonpavde G; Pond G; Godbold J; Oh WK; Bamias A
Urol Oncol; 2014 Jan; 32(1):48.e1-8. PubMed ID: 24055428
[TBL] [Abstract][Full Text] [Related]
7. Design and endpoints of clinical trials in hepatocellular carcinoma.
Llovet JM; Di Bisceglie AM; Bruix J; Kramer BS; Lencioni R; Zhu AX; Sherman M; Schwartz M; Lotze M; Talwalkar J; Gores GJ;
J Natl Cancer Inst; 2008 May; 100(10):698-711. PubMed ID: 18477802
[TBL] [Abstract][Full Text] [Related]
8. Treatment of metastatic urothelial cancer: opportunities for drug discovery and development.
Sonpavde G; Sternberg CN
BJU Int; 2008 Nov; 102(9 Pt B):1354-60. PubMed ID: 19035904
[TBL] [Abstract][Full Text] [Related]
9. Editorial comment on: Impact of multimodal treatment on survival in patients with metastatic urothelial cancer.
Bamias A
Eur Urol; 2007 Oct; 52(4):1113-4. PubMed ID: 17367916
[No Abstract] [Full Text] [Related]
10. Novel agents for muscle-invasive and advanced urothelial cancer.
Sonpavde G; Ross R; Powles T; Sweeney CJ; Hahn N; Hutson TE; Galsky MD; Lerner SP; Sternberg CN
BJU Int; 2008 Apr; 101(8):937-43. PubMed ID: 18005203
[TBL] [Abstract][Full Text] [Related]
11. Clinical trials referral resource. Current phase II and phase III clinical trials in the treatment of colorectal cancer.
Mooney MM; Schoenfeldt M
Oncology (Williston Park); 2004 Oct; 18(11):1396, 1401, 1404 passim. PubMed ID: 15609469
[No Abstract] [Full Text] [Related]
12. Immune Checkpoint Inhibition in Metastatic Urothelial Cancer.
Powles T; Smith K; Stenzl A; Bedke J
Eur Urol; 2017 Oct; 72(4):477-481. PubMed ID: 28413128
[TBL] [Abstract][Full Text] [Related]
13. Reactive oxygen species may have antitumor activity in metastatic melanoma.
Tuma RS
J Natl Cancer Inst; 2008 Jan; 100(1):11-2. PubMed ID: 18159075
[No Abstract] [Full Text] [Related]
14. Eleven years: the long and winding road.
Ramondetta LM; Jhingran A
Gynecol Oncol; 2007 Nov; 107(2):166-8. PubMed ID: 17950382
[No Abstract] [Full Text] [Related]
15. Chemotherapy for recurrent cervical cancer.
Pectasides D; Kamposioras K; Papaxoinis G; Pectasides E
Cancer Treat Rev; 2008 Nov; 34(7):603-13. PubMed ID: 18657909
[TBL] [Abstract][Full Text] [Related]
16. Incorporating novel treatment strategies into conventional therapy.
Estey EH
Clin Adv Hematol Oncol; 2009 Jun; 7(6):4-7. PubMed ID: 19645129
[No Abstract] [Full Text] [Related]
17. [Standard chemotherapy for gastric cancer].
Sasaki T; Kobayashi T; Okamoto R; Omuro Y
Nihon Rinsho; 2001 Apr; 59 Suppl 4():350-7. PubMed ID: 11424405
[No Abstract] [Full Text] [Related]
18. A phase II trial of methotrexate, cisplatin, 5-fluorouracil, and leucovorin in the treatment of invasive and metastatic urothelial carcinoma.
Droller MJ
J Urol; 2000 May; 163(5):1601. PubMed ID: 10798920
[No Abstract] [Full Text] [Related]
19. Relapse pattern of GOG 122 trial should be more informative.
Ozyar E; Genc M
J Clin Oncol; 2006 Aug; 24(22):3709-10; author reply 3710. PubMed ID: 16877741
[No Abstract] [Full Text] [Related]
20. Bladder cancer clinical trials.
Lerner SP
Urol Oncol; 2005; 23(4):275-9. PubMed ID: 16018944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
